2023/04/10
Keio University School of Medicine
Sumitomo Pharma Co., Ltd.
i2medical LLC
A research group led by Project Professor Toshiro Kishimoto of the Keio University School of Medicine, Sumitomo Pharma Co., Ltd. (Head Office: Osaka; Representative Director, President and CEO: Hiroshi Nomura), and i2medical LLC (Development Manager: Kuo-ching Liang) announce that "SWIFT" (tentative name), a program to support the detection and severity assessment of depression which the three parties are jointly developing for practical application, has been designated by the Ministry of Health, Labour and Welfare as the first Software as a Medical Device (SaMD) for priority review.
Please see below for the full press release.